PRACTICE Guidelines REGISTRATION PLATFORM
News MORE
  • 2023.0306

    The Development of Reporting Guideline of clinical Practice Guidelines in General Practice provides detailed guidance for the makers and writers of the general practice guidelines, which will further improve the reporting quality of the general practice guidelines, especially the Chinese general practice guidelines, and promote the application in general medical practice, thus finally improving the quality of primary medical care.

  • 2023.0220

    Professor Gordon Guyatt of McMaster University and Professor Victor Montori of the Mayo Clinic jointly published a paper in the British Medical Journal (BMJ) entitled: Guidelines should consider clinicians' time needed to treat on January 3, 2023.

  • 2022.1126

    IGEST is a generic tool for screening guidelines for any specialty, target population, and healthcare organization, but it is intended only as a screening tool, primarily for quickly assessing guideline quality and determining whether they can be adopted or adapted in other settings, and is not a substitute for some of the more complex guideline quality evaluation tools.

  • 2022.1031

    In July 2022, Jose F. Meneses-Echavez et al. from the Norwegian Institute of Public Health published an article in the Journal of Clinical Epidemiology entitled "Evidence to decision frameworks enabled structured and explicit development of healthcare recommendations". The aim of this study was to identify and describe the processes suggested for the formulation of healthcare recommendations in healthcare guidelines available in guidance documents.

Register MORE
  • 2024.0327
    Total joint arthroplasty (TJA) is considered one of the most successful orthopedic surgeries since the 20th century, and is also recognized as one of the most effective methods for treating end-stage hip and knee joint diseases. Under traditional surgical methods, the implantation of joint prostheses largely relies on the surgeon's experience, which leads to significant blindness and uncertainty. There may be poor placement of prosthetic positions, deviation of force lines, and imbalance of internal and external flexion and extension gaps, which are the main causes of postoperative complications such as dislocation of prostheses, unequal length of lower limbs, poor patellar trajectory, pad wear, and postoperative instability. Therefore, a considerable number of patients still have poor postoperative outcomes. Since the emergence of the Robodoc robot system, with the deepening understanding of the concepts of intelligence, precision, and personalization, surgical robots have flourished in the field of joint surgery. TJA robots can achieve precise and personalized surgical planning, and assist surgeons in installing osteotomy tools, cutting osteotomy, grinding files, and installing prostheses during surgery, improving the accuracy and safety of joint replacement surgery, achieving the goals of reducing perioperative complications, accelerating recovery, and improving long-term efficacy. However, some studies have shown that due to insufficient theoretical knowledge and operational standards, the incidence of complications after some robot assisted joint arthroplasties is increased, and the clinical efficacy is poor. At present, there is a lack of guidance on the clinical practice of robot assisted (RA) hip and knee arthroplasty surgery in China. Therefore, it is necessary to develop clinical practice guidelines based on existing literature evidence to standardize or guide clinical doctors in implementing robot assisted hip and knee replacement surgery. To address the aforementioned issues, a manual will be developed based on the World Health Organization (WHO) guidelines, and a clinical guideline for robot assisted hip and knee arthroplasty surgery will be developed using methods such as the grading of recommendations assessment, development and evaluation (GRADE).
  • 2024.0326
    Excessive Daytime Sleepiness (EDS) refers to the inability of an individual to maintain the necessary alertness and wakefulness during the day, leading to excessive sleep needs or involuntary sleep onset. EDS is often a consequence of sleep deprivation, poor nighttime sleep, other sleep disorders such as obstructive sleep apnea (OSA) and circadian rhythm disturbances. EDS can also be a core symptom of central hypersomnia disorders like narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome. Additionally, it may result from neurodegenerative diseases, psychiatric disorders, endocrine disorders, respiratory diseases, or certain medications. In the United States, the prevalence of EDS in adults is 23.34%, more common in younger women, individuals with low income or unemployment, and often associated with psychiatric disorders or chronic diseases. In Chinese children and adolescents, the prevalence of EDS is 29.2%, varying from 19.8% before puberty to 47.8% after puberty. The prevalence of EDS in the elderly is relatively lower, with a rate of 9.3% in rural Chinese populations aged 65 and above, peaking at ages 65-69 and decreasing with age. EDS significantly disrupts patients' daily lives, work, study, and social interactions. Surveys indicate that EDS contributes to traffic accidents annually, ranking just below accidents caused by nighttime fatigue driving and drunk driving. healthcare workers with EDS may also face increased risks of medical errors[8]. Moreover, EDS is associated with an increased risk of cardiovascular, mental health and neurodegenerative diseases as well as mortality. The etiology of EDS is complex and highly heterogeneous, potentially persisting for several years and requiring individualized interventions. Treatment for EDS include non-pharmacological and pharmacological therapies targeting underlying causes or symptoms of EDS. Wake-promoting drugs are a primary approach to improving EDS symptoms other than intervening in primary diseases. These drugs are categorized into approved indications for EDS and off-label applications. In China, modafinil and pitolisant are already approved for EDS. More wake-promoting agents may receive approval in the future such as solriamfetol which has initiated Phase III clinical trials for EDS due to OSA in China. Additionally, there are off-label applications of methylphenidate and amphetamine. Given the high prevalence and risks associated with EDS, intervention management is crucial. The current Chinese consensus guidelines for EDS focus on comprehensive management without specific consensus on the clinical application of wake-promoting drugs. Considering the approval of wake-promoting agents for EDS in China and the increasing variety of approved agents along with off-label treatments available, there is a lot unmet clinical needs regarding wake-promoting drugs by establishing standardized clinical guidelines for their use. Therefore, this consensus aims to provide unified guidance on drug selection for EDS, initiation criteria, treatment strategies, personalized therapy approaches, safety monitoring, and potential directions for future research.
Registration process and operational mode of a CPG registry